No Data
No Data
Express News | Block orders continued to increase their positions in computer stocks while selling off electronic stocks.
A-shares banks, insurance sector strengthen against the market, Hubei Biocause Pharmaceutical rose nearly 3%.
On September 18, Hubei Biocause Pharmaceutical rose nearly 3%, previously hitting the limit down; China Life Insurance, China Pacific Insurance, Postal Savings Bank of China, Bank of China, and Industrial and Commercial Bank of China all rose more than 1%.
Hubei Biocause Pharmaceutical's Insurance Unit Logs 29 Billion Yuan Premium Income in January-August Period; Shares Down 3%
The A-share internet insurance market is generally down, with Hubei Biocause Pharmaceutical hitting the lower limit of daily trading.
On September 18, Hubei Biocause Pharmaceutical hit the limit down, Qitian Technology dropped more than 7%, Jiangxi Tianli Technology, ST Kop, Kaisa Jiayun Technology, and others all dropped more than 3%.
Hubei Biocause Pharmaceutical (000627.SZ) subsidiary China Best Life Insurance Co., Ltd. accumulated premium income of approximately 29.03 billion yuan from January to August.
Hubei Biocause Pharmaceutical (000627.SZ) announced that its subsidiary, China Best Life Insurance Co., Ltd., has...
Express News | Hubei Biocause Pharmaceutical: stocks trading abnormally volatile and severely abnormally volatile.
No Data
No Data